Non destinato ai media statunitensi e britannici (NOTIZIA IN BREVE) Il comitato per i medicinali per uso umano dell’Agenzia europea per i medicinali ha raccomandato l’autorizzazione all’immissione in commercio nell’Unione europea di darolutamide, un inibitore orale del recettore degli androgeni, … Read the full press release
Posted in European Union, Germany, Healthcare, News, Pharma & Biotech
Tagged ADT, Agenzia europea per i medicinali, Bayer, carcinoma prostatico, carcinoma prostatico sensibile agli ormoni metastatico, CHMP, Christine Roth, Commissione europea, darolutamide, docetaxel, inibitore, mHSP, nmCRPC, Nubeqa™, Prof. Bertrand Tombal, terapia di privazione degli androgeni
Not intended for U.S. and UK Media (IN BRIEF) The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended darolutamide, an oral androgen receptor inhibitor, for marketing authorization in the European Union as a treatment for patients … Read the full press release
Posted in European Union, Germany, Healthcare, News, Pharma & Biotech
Tagged ADT, androgen deprivation therapy, Bayer, CHMP, Christine Roth, darolutamide, docetaxel, European Commission, European Medicines Agency, inhibitor, metastatic hormone-sensitive prostate cancer, mHSP, nmCRPC, Nubeqa™, Prof. Bertrand Tombal, prostate cancer
New research led by the University of Warwick shows newly diagnosed advanced prostate cancer patients who received the chemotherapy drug docetaxel with standard hormone therapy lived ten months longer on average, compared to those who received standard therapy alone. COVENTRY, … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
